As a Biopharmaceutical company listed on the ASX (ASX:CXS) ChemGenex Pharmaceuticals is a leader in the Australian Biotech sector. Oncology is the primary focus with a developing late stage product pipeline.

Download our latest Annual Report

Download our latest Corporate Presentation

Download a Corporate Factsheet

Download Share Registry details

Latest News

March 2nd, 2010

U.S. Food and Drug Administration (FDA) Sets 22 March for Oncologic Drugs Advisory Committee (ODAC) Meeting to Review OMAPRO™

February 9th, 2010

Extreme Weather in Washington D.C. has Postponed the FDA’s Oncologic Drugs Advisory Committee Meeting Scheduled for 10 February 2010

December 17th, 2009

ChemGenex Pharmaceuticals Announces Omapro™ to be Reviewed by the FDA’s Oncologic Drugs Advisory Committee